Trovagene Inc., a precision medicine biotechnology company, recently announced positive results from preclinical research of PCM-075 with a Histone deacetylase (HDAC) inhibitor in Non-Hodgkin Lymphoma (NHL) cell lines.
Dr. Steven Grant, the associate director for translational research and co-leader of the Developmental Therapeutics Program at Massey Cancer Center, conducted the synergy assessment.
PCM-075 is the company’s investigational Polo-like kinase 1 (PLK1) inhibitor. The drug was used in the research as a combination product to target patients with aggressive double-hit B-cell lymphoma (DLBCL) and mantle-cell lymphoma cell lines. According to research, PCM-075 showed significant synergy when used in combination with an HDAC inhibitor of up to 80 percent.
"We are excited to see the synergistic benefits with PCM-075 in combination with a HDAC inhibitor in the most difficult cell lines in NHL," Trovagene CEO Bill Welch said in a statement. "This data complements our recent announcement of an in-vivo study demonstrating synergy of PCM-075 with a leading investigational FLT3 inhibitor, as well as PCM-075 synergy with many chemotherapeutics. We have an active Investigational New Drug (IND) in place with the FDA for each of solid tumors and hematologic malignancies, which could facilitate the development of PCM-075 across a number of cancer types."